文献速递神经核医学肿瘤 PET/CT

基于主成分分析的PET指标与神经病理分期高度吻合

Principal-Component Analysis-Based Measures of PET Data Closely Reflect Neuropathologic Staging Schemes.
PubMed 文献 · J Nucl Med · 2020-10-23

本研究纳入阿尔茨海默病神经影像学倡议中接受尸检及18F-FDG PET或Aβ PET的患者,验证AD转化相关模式(ADCRP)表达评分与Braak缠结分期及Thal淀粉样蛋白分期的关联。结果显示18F-FDG-ADCRP评分与Braak分期显著相关,Aβ-ADCRP评分与Thal分期显著相关,两者联合识别中高ADNC的AUC达0.98。

要点

  • 18F-FDG-ADCRP表达评分与Braak缠结分期显著相关(ρ>0.48,P<0.005)。
  • Aβ-ADCRP表达评分与Thal淀粉样蛋白分期显著相关(ρ>0.66,P<0.001)。
  • ADCRP联合识别中高ADNC的AUC为0.98,优于单独18F-FDG-ADCRP。

核心结论

  • 18F-FDG-ADCRP表达评分与tau病理范围(Braak分期)高度对应,Aβ-ADCRP是淀粉样病理的有效生物标志物。
  • ADCRP联合识别中高ADNC的AUC为0.98,优于单独18F-FDG-ADCRP。

研究设计与样本

  • 研究纳入阿尔茨海默病神经影像学倡议中接受尸检且具备18F-FDG PET(30例AD、6例MCI、2例认知正常)或Aβ PET(17例AD、3例MCI、2例认知正常)的患者。
  • 将18F-FDG-ADCRP和Aβ-ADCRP的模式表达评分(PES)分别与Braak缠结分期和Thal淀粉样蛋白分期进行比较。
  • 以AD典型低代谢区和淀粉样负荷升高区的平均18F-FDG摄取和平均18F-AV-45 SUVr作为基于感兴趣区的PET指标。

主要发现

  • 18F-FDG-ADCRP的PES与Braak分期显著相关(ρ>0.48,P<0.005),Aβ-ADCRP的PES与Thal分期显著相关(ρ>0.66,P<0.001)。
  • 18F-FDG-ADCRP、Aβ-ADCRP及其联合识别中高ADNC的AUC分别为0.80、0.95和0.98(n=22)。
  • AD典型区平均18F-FDG摄取与Braak分期显著相关(|ρ|>0.45,P<0.01),平均18F-AV-45 SUVr与Thal分期显著相关(ρ>0.55,P<0.01)。
  • 基于感兴趣区的平均18F-FDG摄取、平均18F-AV-45 SUVr及其联合区分ADNC分期的AUC分别为0.79、0.88和0.90(n=22)。
  • 在全部有18F-FDG PET和神经病理信息的受试者中(n=38),18F-FDG-ADCRP的PES是中高ADNC的显著预测因子(AUC=0.72),而平均18F-FDG摄取不是(AUC=0.66),但两种方法差异无统计学意义。

关键数值与推荐

  • 18F-FDG-ADCRP的PES与Braak分期相关:ρ>0.48,P<0.005。
  • Aβ-ADCRP的PES与Thal分期相关:ρ>0.66,P<0.001。
  • ADCRP联合识别中高ADNC的AUC为0.98(n=22)。
  • 基于感兴趣区的平均18F-FDG摄取、平均18F-AV-45 SUVr及其联合区分ADNC分期的AUC分别为0.79、0.88和0.90(n=22)。

临床怎么用

  • 18F-FDG-ADCRP表达评分可用于反映tau病理范围,Aβ-ADCRP表达评分可用于反映淀粉样病理负荷。
  • 联合ADCRP评分可能提高识别中高ADNC的诊断性能,但需进一步验证。

局限性

  • 样本量较小,尤其Aβ PET和联合分析仅n=22。
  • 18F-FDG-ADCRP与平均18F-FDG摄取预测中高ADNC的AUC差异无统计学意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Voxel-based principal-component analysis allows for an identification of patterns of glucose metabolism and amyloid deposition related to the conversion from mild cognitive impairment (MCI) to Alzheimer disease (AD). The present study aimed to validate these AD conversion-related patterns (ADCRPs) against neuropathologic findings. Methods: We included patients from the Alzheimer's Disease Neuroimaging Initiative who underwent autopsy and for whom 18F-FDG PET (30 AD, 6 MCI, 2 cognitively normal) and amyloid-β (Aβ) PET (17 AD, 3 MCI, 2 cognitively normal) were available. Pattern expression scores (PESs) of the 18F-FDG- and Aβ-ADCRP were compared with Braak tangle stage and Thal amyloid phase, respectively. Mean 18F-FDG uptake and mean 18F-AV-45 SUV ratio (SUVr) in regions of hypometabolism and elevated amyloid load typical of AD, respectively, were used as volume-of-interest-based PET measures. The diagnostic performance for identifying none-to-low vs. intermediate-to-high AD neuropathologic change (ADNC) was assessed for all biomarkers. Results: We observed significant associations between PES of 18F-FDG-ADCRP and Braak stage (ρ > 0.48, P < 0.005) and between PES of Aβ-ADCRP and Thal phase (ρ > 0.66, P < 0.001). PES of 18F-FDG-ADCRP, PES of Aβ-ADCRP, and their combination identified intermediate-to-high ADNC with an area under the receiver-operating-characteristic curve (AUC) of 0.80, 0.95, and 0.98 (n = 22), respectively. Mean 18F-FDG uptake and mean 18F-AV-45 SUVr in AD-typical regions were also significantly associated with Braak stage (|ρ| > 0.45, P < 0.01) and Thal phase (ρ > 0.55, P < 0.01), respectively. Volume-of-interest-based PET measures discriminated between ADNC stages with an AUC of 0.79, 0.88, and 0.90 for mean 18F-FDG uptake, mean 18F-AV-45 SUVr, and their combination (n = 22), respectively. Contemplating all subjects with available 18F-FDG PET and neuropathology information (n = 38), PES of 18F-FDG-ADCRP was a significant predictor of intermediate-to-high ADNC (AUC = 0.72), whereas mean 18F-FDG uptake was not (AUC = 0.66), although the difference between methods was not significant. Conclusion: PES of 18F-FDG-ADCRP, a measure of neurodegeneration, shows close correspondence with the extent of tau pathology, as assessed by Braak tangle stage. PES of Aβ-ADCRP is a valid biomarker of underlying amyloid pathology, as demonstrated by its strong correlation with Thal phase. The combination of ADCRPs performed better than 18F-FDG-ADCRP alone, although there was only negligible improvement compared with Aβ-ADCRP.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Blazhenets G, Frings L, Sörensen A, et al. Principal-Component Analysis-Based Measures of PET Data Closely Reflect Neuropathologic Staging Schemes. J Nucl Med. 2020. PMID: 33097630. doi:10.2967/jnumed.120.252783

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。